The role of topotecan in cancer ginecology treatment
The high morbidity, often latent, asymptomatic disease development is not optimal therapy in the first line, causes the development of the frequent recurrence of tumors, requiring second and thirds lines of chemotherapy. The use of topotecan in standard mode is limited by myelosuppression, therefore...
Saved in:
Main Authors: | A. G. Kedrova, V. V. Kosyy, D. A. Astakhov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2017-02-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/525 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014-07-01) -
Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)
by: E. G. Novikova, et al.
Published: (2014-07-01) -
Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life
by: E. G. Novikova, et al.
Published: (2014-08-01) -
Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01) -
Bevacizumab in maintenance therapy for ovarian cancer patients
by: L. Yu. Vladimirova, et al.
Published: (2020-08-01)